Ocrelizumab Treatment Modulates B-Cell Regulating Factors in Multiple Sclerosis

BACKGROUND AND OBJECTIVES: Antibodies to CD20 efficiently reduce new relapses in multiple sclerosis (MS), and ocrelizumab has been shown to be effective also in primary progressive MS. Although anti-CD20 treatments efficiently deplete B cells in blood, some B cells and CD20(−) plasma cells persist i...

Descripción completa

Detalles Bibliográficos
Autores principales: Ho, Samantha, Oswald, Eva, Wong, Hoi Kiu, Vural, Atay, Yilmaz, Vuslat, Tüzün, Erdem, Türkoğlu, Recai, Straub, Tobias, Meinl, Ingrid, Thaler, Franziska, Kümpfel, Tania, Meinl, Edgar, Mader, Simone
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9880874/
https://www.ncbi.nlm.nih.gov/pubmed/36702538
http://dx.doi.org/10.1212/NXI.0000000000200083

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9880874/
https://www.ncbi.nlm.nih.gov/pubmed/36702538
http://dx.doi.org/10.1212/NXI.0000000000200083

Ejemplares similares